CRDF - Company ID 0001213037
Cardiff Oncology, Inc. trades as CRDF. In its fiscal 2025 annual report the company posted revenue of $593.00K, down 13.2% from the prior year and net income of -$45.85K. This page tracks Cardiff Oncology, Inc. through 996 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Cardiff Oncology, Inc.'s revenue grew from $381.07K to $593.00K, a compound annual growth rate of 5.0%. Net profit margin expanded from -10287.7% to -7.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-19 |
| Major company event | 8-K | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 |
| Insider trade | 4 | 2026-04-28 |
| New insider ownership | 3 | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-23 |
The largest companies sharing Cardiff Oncology, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Cardiff Oncology, Inc. reported revenue of $593.00K for fiscal year 2025, a decrease of 13.2% year over year.
In its latest fiscal year Cardiff Oncology, Inc. reported a net loss of $45.85K.